{"organizations": [], "uuid": "681b0a764f8b5f8b8fff00fda64f8d42b127023b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-accepts-bl/brief-astrazeneca-says-u-s-fda-accepts-bla-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-idUSFWN1RG01K", "country": "US", "domain_rank": 408, "title": "BRIEF-Astrazeneca Says ‍U.S. FDA Accepts BLA For Moxetumomab Pasudotox In Hairy Cell Leukaemia​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-03T09:56:00.000+03:00", "replies_count": 0, "uuid": "681b0a764f8b5f8b8fff00fda64f8d42b127023b"}, "author": "", "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-accepts-bl/brief-astrazeneca-says-u-s-fda-accepts-bla-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-idUSFWN1RG01K", "ord_in_thread": 0, "title": "BRIEF-Astrazeneca Says ‍U.S. FDA Accepts BLA For Moxetumomab Pasudotox In Hairy Cell Leukaemia​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "bla", "sentiment": "negative"}, {"name": "u.s. fda", "sentiment": "negative"}, {"name": "brief-astrazeneca says ‍u.s. fda", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}, {"name": "pasudotox in hairy cell leukaemia​ reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astrazeneca plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - Astrazeneca Plc:\n* ‍US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMAB PASUDOTOX IN HAIRY CELL LEUKAEMIA​\n* ‍PHASE III MOXETUMOMAB PASUDOTOX CLINICAL TRIAL MET ITS PRIMARY ENDPOINT​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": [], "published": "2018-04-03T09:56:00.000+03:00", "crawled": "2018-04-03T10:17:36.080+03:00", "highlightTitle": ""}